mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026

View original at globenewswire.com
BioNTech präsentiert auf der 44. J.P…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BioNTech currently expects no revenues from oncology product sales in 2026

    80% confidence

  • 2026 is a year when scientific progress becomes tangible results for BioNTech, with milestones including late-stage data releases, early clinical trial results for combination therapies, and launch of additional Phase 3 trials

    80% confidence

  • BioNTech closed 2025 with strong momentum through consistent execution in R&D, partnerships, acquisitions, and strong financial position while advancing next wave of innovations including combination studies

    80% confidence

  • BioNTech expects collaboration revenues from Bristol Myers Squibb partnership in 2026 to be essentially at 2025 levels

    80% confidence

  • Positive clinical trial results could pave the way for multiple short- and medium-term product launches, bringing BioNTech closer to helping patients with various cancer types

    80% confidence

  • BioNTech expects at least 17 late-stage clinical data readouts through 2030 and beyond, including from registration-enabling studies, to inform decisions on multiple potential product launches and establish BioNTech as a multi-product oncology company by 2030

    80% confidence

  • BioNTech plans to start six additional Phase 3 clinical trials in 2026, bringing total expected Phase 3 trials to 15 by year-end

    80% confidence

  • BioNTech expects moderate decline in Comirnaty revenues in 2026 compared to 2025, reflecting current COVID-19 vaccine market dynamics influenced by changing vaccination recommendations especially in the United States and transition from multi-year contracts to private markets

    80% confidence

  • BioNTech has positioned itself as a biopharmaceutical company with multiple programs in late-stage clinical development

    80% confidence

Data points we hold from this source

BioNTech SE · phase 2 3 trials count25 trials
BioNTech SE · combination therapy trials count10 trials
BioNTech SE · phase 3 trials count15 trials
BioNTech SE · cash17.2 billion_EUR
BioNTech SE · revenue2.6-2.8 billion_EUR

Cité dans ces articles de Via News

Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026 — Source | Via News | fr.VIA.NEWS